Tuberculosis Testing Market: Market Size & Forecast 2026

The TB testing market encompasses a range of diagnostic platforms for detecting Mycobacterium tuberculosis infection across both active and latent disease states. Despite being a preventable and treatable condition, TB remains one of the world's deadliest infectious diseases, sustaining demand for testing across public and private healthcare systems worldwide. Market valuation reflects ongoing investment in both centralized laboratory infrastructure and point-of-care solutions aimed at closing global case detection gaps.

• •Approximately one-quarter of the global population has been infected with TB bacilli, with roughly 10 million new active cases and 1.3 million deaths reported annually
• •Core diagnostic technologies include nucleic acid amplification tests (NAAT), tuberculin skin tests (TST), interferon-gamma release assays (IGRA), and smear microscopy
• •Government procurement, multilateral health programs, and non-governmental funding organizations collectively account for a substantial share of testing purchases in high-burden regions

The WHO End TB Strategy, targeting a 90% reduction in TB incidence and 95% reduction in TB deaths by 2035, continues to motivate national governments and international agencies to invest in expanded screening and rapid diagnostic capacity. The rising emphasis on identifying latent TB infection, particularly among high-risk populations and in low-incidence countries, has broadened the addressable market beyond traditional active-case detection. Advances in molecular diagnostics, including cartridge-based NAAT systems, have compressed time-to-result and enhanced accuracy, making testing increasingly viable in resource-limited settings.

• •Point-of-care molecular tests delivering results in under two hours are being deployed at scale in high-burden, low-resource settings to accelerate treatment initiation
• •Growing recognition of drug-resistant TB (MDR-TB and XDR-TB) has elevated demand for rapid drug-susceptibility testing to guide appropriate therapy
• •Sustained funding from the Global Fund, USAID, and bilateral donors underpins expansion of TB testing infrastructure across Africa, Asia, and Eastern Europe

The market is segmented by technology into molecular diagnostics, immunological tests (TST and IGRA), smear microscopy, and culture-based methods, with molecular platforms representing the fastest-growing segment due to superior sensitivity and capability to detect drug resistance. Geographically, the Asia-Pacific region commands the largest market share, driven by high disease burden across India, China, Indonesia, and the Philippines, while Africa represents the second-largest regional market. North America and Europe, though smaller in volume, exhibit steady growth fueled by latent TB screening programs and testing demand driven by immigration from high-burden regions.

• •Molecular diagnostics currently generate the largest revenue share and are projected to maintain segment dominance through the forecast period
• •Asia-Pacific accounts for the majority of regional market share, with the region home to nearly two-thirds of global TB cases
• •Africa is emerging as a key growth market, supported by international donor funding and expanding national TB program budgets

What are the recent trends and outlook?

The market is expected to sustain its growth trajectory as molecular and point-of-care technologies progressively displace conventional smear microscopy and culture-based methods, particularly in resource-constrained settings. Emerging innovations, including next-generation sequencing, microfluidic cartridge systems, and artificial-intelligence-assisted digital microscopy, promise further gains in diagnostic accuracy, turnaround time, and decentralization. The market's long-term outlook remains tied to global political and financial commitment to TB elimination, though challenges such as pricing pressure in low-income countries, regulatory hurdles for new entrants, and persistent gaps in healthcare access will influence the pace of realized growth.

• •Integration of connected diagnostic devices and digital reporting systems is strengthening disease surveillance, treatment monitoring, and data-driven public health decision-making
• •Biomarker-based research targeting tests that can reliably differentiate active from latent TB infection has the potential to reshape screening strategies and expand addressable demand
• •Achieving projected market growth will depend on continued international funding commitments and the commercialization of cost-effective, high-accuracy tests suited for decentralized, non-laboratory settings